Huntington's Disease Treatment Global Market Report 2025

The Huntington’s disease treatment market size has grown rapidly in recent years. It will grow from $0.73 billion in 2024 to $0.83 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth observed in the historical period can be attributed to several factors, including increased awareness of genetic disorders, improved accessibility to genetic testing, higher investment in neurodegenerative disease research, a rise in the number of clinical trials for experimental therapies, and a growing pipeline of disease-modifying drugs.

The Huntington’s disease treatment market size is expected to see rapid growth in the next few years. It will grow to $1.35 billion in 2029 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period is expected to be driven by a stronger focus on personalized medicine, greater integration of digital health monitoring, increased regulatory support for orphan drugs, rising demand for therapies that provide symptomatic relief, and a higher demand for disease-modifying treatments. Key trends during this period are likely to include advancements in technology-driven gene silencing tools, the development of cell-based therapies, the emergence of peripheral biomarkers, the integration of telehealth into Huntington’s disease care, the incorporation of patient-reported outcomes, and continued innovation in disease-modifying drugs.

The growth of the Huntington’s disease treatment market is expected to be driven by the increasing use of gene therapies, which target genetic causes and slow disease progression. Gene therapies are treatments that alter or replace defective genes to cure or prevent diseases at the genetic level. As precision medicine continues to advance, gene therapies offer the ability to directly target the underlying genetic causes, leading to improved outcomes compared to traditional treatments. In Huntington’s disease, gene therapies aim to silence the defective HTT gene that produces harmful proteins, thus preventing nerve cell damage. This approach helps slow disease progression, protect brain function, and provides potential for long-term control. For example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT) and Citeline reported that the number of gene therapies in phase II clinical trials increased by 5% from 247 to 260 by the end of Q2 2023. As such, the increase in gene therapies is contributing to the market’s growth.

Companies in the Huntington’s disease treatment market are also focusing on the development of advanced therapies, such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, which aim to improve patient quality of life while slowing disease progression. VMAT2 inhibitors work by blocking a protein involved in packaging neurotransmitters for release in the brain. These drugs reduce neurotransmitter release, helping manage involuntary movements and other related symptoms. For example, in August 2023, Neurocrine Biosciences received FDA approval for Ingrezza (valbenazine) capsules, a once-daily oral VMAT2 inhibitor for the treatment of chorea associated with Huntington's disease in adults. This medication helps control involuntary movements by reducing excessive dopamine signaling in the brain and is available in various strengths, offering a convenient dosing option for patients.

In December 2024, PTC Therapeutics, a US-based pharmaceutical company developing treatments for Huntington’s disease, entered into a partnership with Novartis AG to advance the development of PTC518, a potential first-in-class oral, disease-modifying therapy for Huntington’s disease. This collaboration aims to accelerate the development and global commercialization of PTC518. Novartis AG, a Switzerland-based pharmaceutical company, specializes in drugs for Huntington’s disease.

Major players in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Bausch Health Companies Inc., Sun Pharmaceutical Industries Inc., H. Lundbeck A/S, WaVe Life Sciences Ltd., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Annexon Inc., Uniqure NV, Sage Therapeutics Inc., Azevan Pharmaceuticals Inc., Prilenia Therapeutics B.V.

North America was the largest region in the Huntington’s disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in Huntington's disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Huntington's disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Huntington’s disease treatment consists of medical therapies aimed at managing the symptoms of this progressive neurological condition. The main objective is to slow the disease’s progression, reduce symptoms, and improve the patient’s quality of life.

The primary types of treatment for Huntington’s disease are symptomatic treatments and disease-modifying therapies. Symptomatic treatments focus on alleviating the symptoms of Huntington’s disease and enhancing quality of life, without targeting the underlying cause. These treatments are becoming increasingly sought after as patients look for better ways to manage daily challenges. Various methods are used to administer these treatments, including oral, intravenous, subcutaneous, and topical routes, for applications in genetic, neurological, and psychiatric disorders. These treatments are available through multiple distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a wide range of end users, including hospitals, clinics, home care settings, and research institutions.

The Huntington’s disease treatment market research report is one of a series of new reports that provides Huntington’s disease treatment market statistics, including the Huntington’s disease treatment industry's global market size, regional shares, competitors with the Huntington’s disease treatment market share, detailed Huntington’s disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the Huntington’s disease treatment market. This Huntington’s disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The Huntington's disease treatment market consists of sales of products including tetrabenazine, deutetrabenazine, huntingtin-lowering therapies, cannabinoids, and cognitive enhancers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.